NASDAQ · Financial Statements

Intellia Therapeutics, Inc. (NTLA) Financial Statements

$11.42 NASDAQ: NTLA Market Cap $1.60B

Intellia Therapeutics, Inc. most recently reported annual revenue of $68.0M, a net loss of $413.0M. Revenue grew at an average annual rate of 3.2% over the last 5 fiscal years. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.

Annual Financials (USD)

Metric20212022202320242025
Revenue$33.0M$52.0M$36.0M$58.0M$68.0M
Operating Profit$-268.0M$-458.0M$-515.0M$-534.0M$-441.0M
Net Profit$-268.0M$-474.0M$-481.0M$-519.0M$-413.0M
EPS$-3.78$-6.16$-5.42$-5.25$-3.81
Op Margin-810.4%-879.0%-1420.5%-923.1%-651.7%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$1.3B$1.5B$1.3B$1.2B$842.0M
Total Liabilities$254.0M$285.0M$251.0M$319.0M$171.0M
Cash$123.0M$524.0M$227.0M$189.0M$155.0M
Borrowings$74.0M$131.0M$115.0M$210.0M$93.0M

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-225.0M$-333.0M$-394.0M$-349.0M$-349.0M
Investing Cash Flow$-564.0M$102.0M$-45.0M$120.0M$120.0M
Financing Cash Flow$43.0M$17.0M$11.0M$9.0M$54.0M
Net Cash Flow$-39.0M$410.0M$-295.0M$-38.0M$-38.0M
Free Cash Flow$-238.0M$-392.0M$-408.0M$-355.0M$-355.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.10
EV / EBITDA-4.30
FCF Yield-27.21%
Quick Ratio6.65
Interest Coverage—
Return 1Y-22.05%
Return 3Y-73.52%
Return 5Y-90.37%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
NTLA Overview NTLA Dividend Run Stock Screener

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.